Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)

Nandini Verma; Anna Katharina Muller; Charu Kothari; Effrosini Panayotopoulou; Amir Kedan; Michael Selitrennik; Gordon B. Mills; Lan K. Nguyen; Sungyoung Shin; Thomas Karn; Uwe Holtrich; Sima Lev

doi:10.1158/0008-5472.CAN-19-3573

Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)

Nandini Verma, Anna Katharina Muller, Charu Kothari, Effrosini Panayotopoulou, Amir Kedan, Michael Selitrennik, Gordon B. Mills, Lan K. Nguyen, Sungyoung Shin, Thomas Karn, Uwe Holtrich, Sima Lev

Cell Developmental and Cancer Biology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.

Original language	English (US)
Pages (from-to)	362
Number of pages	1
Journal	Cancer Research
Volume	80
Issue number	2
DOIs	https://doi.org/10.1158/0008-5472.CAN-19-3573
State	Published - Jan 15 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/0008-5472.CAN-19-3573

Fingerprint

Dive into the research topics of 'Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)'. Together they form a unique fingerprint.

Cite this

Verma, N., Muller, A. K., Kothari, C., Panayotopoulou, E., Kedan, A., Selitrennik, M., Mills, G. B., Nguyen, L. K., Shin, S., Karn, T., Holtrich, U., & Lev, S. (2020). Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797). Cancer Research, 80(2), 362. https://doi.org/10.1158/0008-5472.CAN-19-3573

Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797). / Verma, Nandini; Muller, Anna Katharina; Kothari, Charu et al.
In: Cancer Research, Vol. 80, No. 2, 15.01.2020, p. 362.

Research output: Contribution to journal › Comment/debate › peer-review

Verma, N, Muller, AK, Kothari, C, Panayotopoulou, E, Kedan, A, Selitrennik, M, Mills, GB, Nguyen, LK, Shin, S, Karn, T, Holtrich, U & Lev, S 2020, 'Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)', Cancer Research, vol. 80, no. 2, pp. 362. https://doi.org/10.1158/0008-5472.CAN-19-3573

Verma N, Muller AK, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M et al. Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797). Cancer Research. 2020 Jan 15;80(2):362. doi: 10.1158/0008-5472.CAN-19-3573

@article{5b1fc28d451440bc868ce82b823308cf,

title = "Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)",

abstract = "In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.",

author = "Nandini Verma and Muller, {Anna Katharina} and Charu Kothari and Effrosini Panayotopoulou and Amir Kedan and Michael Selitrennik and Mills, {Gordon B.} and Nguyen, {Lan K.} and Sungyoung Shin and Thomas Karn and Uwe Holtrich and Sima Lev",

note = "Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",

year = "2020",

month = jan,

day = "15",

doi = "10.1158/0008-5472.CAN-19-3573",

language = "English (US)",

volume = "80",

pages = "362",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "2",

}

TY - JOUR

T1 - Correction

T2 - Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)

AU - Verma, Nandini

AU - Muller, Anna Katharina

AU - Kothari, Charu

AU - Panayotopoulou, Effrosini

AU - Kedan, Amir

AU - Selitrennik, Michael

AU - Mills, Gordon B.

AU - Nguyen, Lan K.

AU - Shin, Sungyoung

AU - Karn, Thomas

AU - Holtrich, Uwe

AU - Lev, Sima

PY - 2020/1/15

Y1 - 2020/1/15

N2 - In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.

AB - In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.

UR - http://www.scopus.com/inward/record.url?scp=85077820145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077820145&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-19-3573

DO - 10.1158/0008-5472.CAN-19-3573

M3 - Comment/debate

C2 - 31941679

AN - SCOPUS:85077820145

SN - 0008-5472

VL - 80

SP - 362

JO - Cancer Research

JF - Cancer Research

IS - 2

ER -

Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this